PXT3003 containing baclofen, naltrexone, and D-sorbitol was produced using genome data, and Artificial Intelligence (AI) technology reduced the expression of PMP22 and improved sensory function in CMT1A patients. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.